Status:

COMPLETED

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Lymphocytic Leukemia, Chronic

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-...

Eligibility Criteria

Inclusion

  • Immunologically confirmed diagnosis of B-cell CLL
  • Rai stage I-IV disease with evidence of progression
  • No previous chemotherapy, radiotherapy, or immunotherapy for B-cell CLL
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Exclusion

  • Active secondary malignancy or transformation to aggressive lymphoma
  • Medical condition requiring chronic use of oral corticosteroids at a dose of 1 mg/kg or 60 mg/m\^2 over 2 weeks
  • Prior treatment with interferon, rituximab or another monoclonal antibody, immunosuppressive treatment or radiotherapy before inclusion to the study
  • History of other malignancies within 2 years before study entry, except for dequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent

Key Trial Info

Start Date :

July 21 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 14 2015

Estimated Enrollment :

128 Patients enrolled

Trial Details

Trial ID

NCT00718549

Start Date

July 21 2009

End Date

September 14 2015

Last Update

August 20 2018

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

City Clinical Hospital #9

Minsk, Belarus, 220116

2

Medical University, Independent Public Clinical Hospital; Dept. of Hematology, SPSK

Bialystok, Poland, 15-276

3

Szpital Uniwersytecki W Krakowie; Klinika Hematologii

Krakow, Poland, 31-501

4

Medical University School; Dept. of Haematology

Lodz, Poland, 93-510